417 related articles for article (PubMed ID: 33294122)
1. The Nrf2/PGC1
Deng X; Lin N; Fu J; Xu L; Luo H; Jin Y; Liu Y; Sun L; Su J
Oxid Med Cell Longev; 2020; 2020():4830418. PubMed ID: 33294122
[TBL] [Abstract][Full Text] [Related]
2. PGC1α promotes cisplatin resistance in human ovarian carcinoma cells through upregulation of mitochondrial biogenesis.
Shen L; Sun B; Sheng J; Yu S; Li Y; Xu H; Su J; Sun L
Int J Oncol; 2018 Jul; 53(1):404-416. PubMed ID: 29749474
[TBL] [Abstract][Full Text] [Related]
3. PGC1α regulates mitochondrial oxidative phosphorylation involved in cisplatin resistance in ovarian cancer cells via nucleo-mitochondrial transcriptional feedback.
Shen L; Zhou L; Xia M; Lin N; Ma J; Dong D; Sun L
Exp Cell Res; 2021 Jan; 398(1):112369. PubMed ID: 33220258
[TBL] [Abstract][Full Text] [Related]
4. PGC1α Promotes Cisplatin Resistance in Ovarian Cancer by Regulating the HSP70/HK2/VDAC1 Signaling Pathway.
Li Y; Kang J; Fu J; Luo H; Liu Y; Li Y; Sun L
Int J Mol Sci; 2021 Mar; 22(5):. PubMed ID: 33802591
[TBL] [Abstract][Full Text] [Related]
5. Recovery of miR-139-5p in Ovarian Cancer Reverses Cisplatin Resistance by Targeting C-Jun.
Jiang Y; Jiang J; Jia H; Qiao Z; Zhang J
Cell Physiol Biochem; 2018; 51(1):129-141. PubMed ID: 30439707
[TBL] [Abstract][Full Text] [Related]
6. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
[TBL] [Abstract][Full Text] [Related]
7. Long non-coding RNA Linc00312 modulates the sensitivity of ovarian cancer to cisplatin via the Bcl-2/Caspase-3 signaling pathway.
Zhang C; Wang M; Shi C; Shi F; Pei C
Biosci Trends; 2018 Jul; 12(3):309-316. PubMed ID: 29952351
[TBL] [Abstract][Full Text] [Related]
8. Mitochondrial and Cytosolic One-Carbon Metabolism Is a Targetable Metabolic Vulnerability in Cisplatin-Resistant Ovarian Cancer.
Wallace-Povirk A; O'Connor C; Dekhne AS; Bao X; Nayeen MJ; Schneider M; Katinas JM; Wong-Roushar J; Kim S; Polin L; Li J; Back JB; Dann CE; Gangjee A; Hou Z; Matherly LH
Mol Cancer Ther; 2024 Jun; 23(6):809-822. PubMed ID: 38377173
[TBL] [Abstract][Full Text] [Related]
9. Low expression of FXYD5 reverses the cisplatin resistance of epithelial ovarian cancer cells.
Liu YK; Jia YJ; Liu SH; Shi HJ; Ma J
Histol Histopathol; 2021 May; 36(5):535-545. PubMed ID: 33570156
[TBL] [Abstract][Full Text] [Related]
10. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
11. Tripterygium glycosides reverse chemotherapy resistance in ovarian cancer by targeting the NRF2/GPX4 signal axis to induce ferroptosis of drug-resistant human epithelial ovarian cancer cells.
Ma B; Zhong Y; Chen R; Zhan X; Huang G; Xiong Y; Tan B
Biochem Biophys Res Commun; 2023 Jul; 665():178-186. PubMed ID: 37163938
[TBL] [Abstract][Full Text] [Related]
12. FSTL1 increases cisplatin sensitivity in epithelial ovarian cancer cells by inhibition of NF-κB pathway.
Liu YK; Jia YJ; Liu SH; Ma J
Cancer Chemother Pharmacol; 2021 Mar; 87(3):405-414. PubMed ID: 33392640
[TBL] [Abstract][Full Text] [Related]
13. p62/SQSTM1 is involved in cisplatin resistance in human ovarian cancer cells via the Keap1-Nrf2-ARE system.
Xia M; Yu H; Gu S; Xu Y; Su J; Li H; Kang J; Cui M
Int J Oncol; 2014 Dec; 45(6):2341-8. PubMed ID: 25269472
[TBL] [Abstract][Full Text] [Related]
14. Modulation of cisplatin sensitivity in human ovarian carcinoma A2780 and SKOV3 cell lines by sulforaphane.
Hunakova L; Gronesova P; Horvathova E; Chalupa I; Cholujova D; Duraj J; Sedlak J
Toxicol Lett; 2014 Nov; 230(3):479-86. PubMed ID: 25159039
[TBL] [Abstract][Full Text] [Related]
15. Diallyl trisulfide alleviates chemotherapy sensitivity of ovarian cancer via the AMPK/SIRT1/PGC1α pathway.
Wang Z; Yan Y; Lou Y; Huang X; Liu L; Weng Z; Cui Y; Wu X; Cai H; Chen X; Ji Y
Cancer Sci; 2023 Feb; 114(2):357-369. PubMed ID: 36309839
[TBL] [Abstract][Full Text] [Related]
16. PACT cessation overcomes ovarian cancer cell chemoresistance to cisplatin by enhancing p53-mediated apoptotic pathway.
Yang X; Zhang Q; Yang X; Zhao M; Yang T; Yao A; Tian X
Biochem Biophys Res Commun; 2019 Apr; 511(4):719-724. PubMed ID: 30827507
[TBL] [Abstract][Full Text] [Related]
17. Alkaloids from Stephania venosa as Chemo-Sensitizers in SKOV3 Ovarian Cancer Cells via Akt/NF-κB Signaling.
Mon MT; Yodkeeree S; Punfa W; Pompimon W; Limtrakul P
Chem Pharm Bull (Tokyo); 2018; 66(2):162-169. PubMed ID: 29386467
[TBL] [Abstract][Full Text] [Related]
18. Soluble CD40 ligands sensitize the epithelial ovarian cancer cells to cisplatin treatment.
Qin L; Qiu H; Zhang M; Zhang F; Yang H; Yang L; Jia L; Qin K; Jia L; Dou X; Cheng L; Sang M; Zhang C; Shan B; Zhang Z
Biomed Pharmacother; 2016 Apr; 79():166-75. PubMed ID: 27044825
[TBL] [Abstract][Full Text] [Related]
19. Forkhead Box Protein C2 Promotes Epithelial-Mesenchymal Transition, Migration and Invasion in Cisplatin-Resistant Human Ovarian Cancer Cell Line (SKOV3/CDDP).
Li C; Ding H; Tian J; Wu L; Wang Y; Xing Y; Chen M
Cell Physiol Biochem; 2016; 39(3):1098-110. PubMed ID: 27562816
[TBL] [Abstract][Full Text] [Related]
20. Sulforaphane enhances the cisplatin sensitivity through regulating DNA repair and accumulation of intracellular cisplatin in ovarian cancer cells.
Gong TT; Liu XD; Zhan ZP; Wu QJ
Exp Cell Res; 2020 Aug; 393(2):112061. PubMed ID: 32437713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
